Content and data provided by various third parties and Fidelity − Terms of Use

Stock Details

RELATED RESOURCES

News & Events:ASMB

ASSEMBLY BIOSCIENCES INC

3.37Up 0.07 (2.1212 %)as of 4:00:00pm ET 09/24/2021

Quotes delayed at least 15 min. Log in for real time quote.

Log in for more news Show all article details.Expand all| Hide all article details.Collapse all
  1. Show article details.

    BRIEF-Assembly Bio Announces Decision To Discontinue Clinical Development Of AbI-H2158

    Reuters – 4:21 PM ET 09/01/2021

    Assembly Biosciences Inc (ASMB): * ASSEMBLY BIO ANNOUNCES DECISION TO DISCONTINUE CLINICAL DEVELOPMENT OF ABI-H2158. * ASSEMBLY BIO - DECISION TO DISCONTINUE DEVELOPMENT OF ABI-H2158 FOLLOWS OBSERVATION OF ELEVATEDALANINE TRANSAMINASE LEVELS IN PHASE 2 STUDY.
  2. Show article details.

    Assembly Bio Announces Decision to Discontinue Clinical Development of ABI-H2158

    GlobeNewswire – 4:02 PM ET 09/01/2021

    --Decision follows observation of elevated alanine transaminase levels in Phase 2 study--Company will focus on advancing ongoing triple combination studies and earlier pipeline candidates Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus, today announced its decision to discontinue development of ABI-H2158 following...
  3. Show article details.

    BRIEF-Assembly Bio Selects Fourth Hbv Core Inhibitor Candidate For Advancement Into Clinical Development

    Reuters – 8:17 AM ET 08/18/2021

    Assembly Biosciences Inc (ASMB): * ASSEMBLY BIO SELECTS FOURTH HBV CORE INHIBITOR CANDIDATE FOR ADVANCEMENT INTO CLINICAL DEVELOPMENT. * ASSEMBLY BIOSCIENCES (ASMB) - SELECTED A FOURTH CORE INHIBITOR CANDIDATE ABI-4334 TO ADVANCE INTO CLINICAL DEVELOPMENT.
  4. Show article details.

    Assembly Bio Selects Fourth HBV Core Inhibitor Candidate for Advancement Into Clinical Development

    GlobeNewswire – 8:00 AM ET 08/18/2021

    Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus, today announced it has selected a fourth core inhibitor candidate, ABI-4334, that has been optimized for potency, to advance into clinical development.
  5. Show article details.

    Assembly Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights

    GlobeNewswire – 4:01 PM ET 08/05/2021

     ASSEMBLY BIOSCIENCES, INC. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus, today reported financial results and recent highlights for the second quarter ended June 30, 2021. “With Assembly Bio’s singular focus to pursue finite and curative treatment regimens for HBV, we continue to advance our clinical programs with urgency.
  6. Show article details.

    Assembly Bio Announces Key Promotions to Leadership Team

    GlobeNewswire – 8:00 AM ET 08/03/2021

     Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus, today announced the promotions of Jason Okazaki to chief operating officer and Michael Samar to chief financial officer.
  7. Show article details.

    BRIEF-Assembly Biosciences Inc - With Michael Houghton'S Appointment To Board, Size Of Board Increased From Eight Directors To Nine Directors

    Reuters – 5:12 PM ET 07/20/2021

    Assembly Biosciences Inc (ASMB): * Assembly Biosciences Inc (ASMB) - WITH MICHAEL HOUGHTON'S APPOINTMENT TO BOARD, SIZE OF BOARD INCREASED FROM EIGHT DIRECTORS TO NINE DIRECTORS Source text for Eikon: [https://bit.ly/3ByWVOy] Further company coverage:
  8. Show article details.

    BRIEF-Nobel Laureate Dr. Michael Houghton Appointed to Assembly Biosciences Board of Directors

    Reuters – 8:33 AM ET 07/20/2021

    Assembly Biosciences Inc (ASMB): * NOBEL LAUREATE DR. MICHAEL HOUGHTON APPOINTED TO ASSEMBLY BIOSCIENCES BOARD OF DIRECTORS Source text for Eikon: Further company coverage:
  9. Show article details.

    Nobel Laureate Dr. Michael Houghton Appointed to Assembly Biosciences Board of Directors

    GlobeNewswire – 8:00 AM ET 07/20/2021

    Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus, today announced that Sir Michael Houghton, PhD, has been appointed to the company’s board of directors. “For more than 30 years, I’ve witnessed Mike’s perseverance and unwavering drive to solve complex scientific challenges related to viral hepatitis.
  10. Show article details.

    Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    GlobeNewswire – 5:00 PM ET 07/02/2021

    Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus, today announced grants of stock options to three new employees to purchase an aggregate of 21,520 shares of the Company’s common stock with an exercise price of $3.82 per share, the closing price of Assembly Bio’s common stock on July 1, 2021.
  11. Show article details.

    Assembly Biosciences Presents Data from HBV Core Inhibitor Programs at the International Liver Congress™ EASL 2021

    GlobeNewswire – 8:00 AM ET 06/23/2021

    Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus, today announced data from its three clinical-stage core inhibitor programs, vebicorvir, ABI-H2158, and ABI-H3733, in an oral presentation and two poster presentations during the International Liver Congress™ 2021, the Annual Meeting of the European Association for t...
  12. Show article details.

    Assembly Biosciences to Present Data from HBV Core Inhibitor Programs at The International Liver Congress™ EASL 2021

    GlobeNewswire – 8:00 AM ET 06/09/2021

    Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus, today announced that three abstracts have been accepted for presentation during the International Liver Congress™ 2021, the Annual Meeting of the European Association for the Study of the Liver taking place virtually June 23-26, 2021.
  13. Show article details.

    Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    GlobeNewswire – 5:00 PM ET 06/04/2021

    Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus, today announced grants of stock options to six new employees to purchase an aggregate of 106,520 shares of the Company’s common stock with an exercise price of $4.03 per share, the closing price of Assembly Bio’s common stock on June 1, 2021.
  14. Show article details.

    Dr. Lisa Johnson-Pratt Joins Assembly Biosciences Board of Directors

    GlobeNewswire – 8:00 AM ET 05/24/2021

    Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus, today announced that Lisa Johnson-Pratt, M.D., has joined the company’s board of directors.
  15. Show article details.

    Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    GlobeNewswire – 5:00 PM ET 05/07/2021

    Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus, today announced grants of stock options to three new employees to purchase an aggregate of 25,000 shares of the Company’s common stock with an exercise price of $4.16 per share, the closing price of Assembly Bio’s common stock on May 3, 2021.
  16. Show article details.

    Assembly Biosciences Reports First Quarter 2021 Financial Results and Recent Updates

    GlobeNewswire – 4:05 PM ET 05/06/2021

    Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus, today reported financial results and recent updates for the first quarter ended March 31, 2021.
Page:

Today's and Upcoming Events

  • Nov
    03

    ASMB to announce Q3 earnings (Unconfirmed)

Past Events (last 90 days)

  • Aug
    05

    ASMB announced Q2 earnings.

Data provided by Thomson Reuters © 2021

Technical Events

Classic Patterns (past 90 days)

PROVIDED BY RECOGNIA, INC.

View All Technical Analysis in Advanced Chart Opens in New Window

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.

Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
Copyright 1998–2021 FMR LLC. 
All rights reserved. 
Close
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.